Iris Schrader

4.3k citations

27 papers · 2.2k indexed · 1 hit paper · h-index 12

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Cancer Research top 2%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies

Papers in ⓘ

Cancer Research 17
- Breast Cancer Treatment Studies 14
- Cancer Genomics and Diagnostics 5
Oncology 25
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 9
- Cancer Cells and Metastasis 8
- Colorectal Cancer Treatments and Studies 2

Co-authors: Gϋnter von Minckwitz (16 shared papers)Sibylle Loibl (16 shared papers)Martina Komor (3 shared papers)Marc Roller (2 shared papers)Christine Solbach (7 shared papers)Claus Hanusch (5 shared papers)Carsten Denkert (4 shared papers)Silvia Darb‐Esfahani (4 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Breast Care (4 papers)Cancer Research (3 papers)Clinical Cancer Research (2 papers)Breast Cancer Research and Treatment (2 papers)
Partner nations: Germany Switzerland Austria

In The Last Decade

Iris Schrader

25 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer 2009 · 1.3k citations

Peers

Countries citing papers authored by Iris Schrader

Since Specialization

Citations

This map shows the geographic impact of Iris Schrader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Schrader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Schrader more than expected).

Fields of papers citing papers by Iris Schrader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Schrader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Schrader. The network helps show where Iris Schrader may publish in the future.

Co-authors

The 25 scholars most cited alongside Iris Schrader, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Iris Schrader Line = papers co-authored together Iris Schrader links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Journal of Clinical Oncology ·Carsten Denkert, Sibylle Loibl, Aurelia Noske, Marc Roller, Berit Müller, Martina Komor, Jan Budczies, Silvia Darb‐Esfahani, Ralf Kronenwett, Claus Hanusch, Christian von Törne, Wilko Weichert, Knut Engels, Christine Solbach, Iris Schrader, Manfred Dietel, Gϋnter von Minckwitz Hit paper breakdown →	2009	1295
2	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gϋnter von Minckwitz, Klaus Pantel	2010	398
3	Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) Annals of Oncology ·B. Gerber, Sibylle Loibl, Holger Eidtmann, Mahdi Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Iris Schrader, K. Kittel, Claus Hanusch, R. Kreienberg, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Jens Huober, Maik Hauschild, Valentina Nekljudova, Michael Untch, Gϋnter von Minckwitz	2013	105
4	HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer Breast Care ·Nadia Harbeck, Matthias W. Beckmann, Achim Rody, Andreas Schneeweiß, Volkmar Müller, Tanja Fehm, Norbert Marschner, Oleg Gluz, Iris Schrader, Georg Heinrich, Michael Untch, Christian Jackisch	2013	84
5	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gϋnter von Minckwitz, Michael Untch, Klaus Pantel	2017	82
6	Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) Breast Cancer Research and Treatment ·Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Sibylle Loibl, Jens Huober, Hans Tesch, Christine Solbach, Frank Holms, Holger Eidtmann, K. Dietrich, Marianne Just, Michael Clemens, Claus Hanusch, Iris Schrader, Stephan Henschen, G. M. Hoffmann, Katharina Tiemann, Kurt Diebold, Michael Untch, Carsten Denkert	2011	35
7	First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial European Journal of Cancer ·M. Kaufmann, Nicolaì Maass, Serban Dan Costa, Andreas Schneeweiß, Sibylle Loibl, Marc Sütterlin, Iris Schrader, B. Gerber, Wolfgang Bauer, W. Wiest, O. Tomé, Andrea Distelrath, Volker Hagen, Anke Kleine-Tebbe, Eugen Ruckhaeberle, K. Mehta, Gϋnter von Minckwitz	2010	30
8	Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). Journal of Clinical Oncology ·B. Gerber, Holger Eidtmann, M. Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Iris Schrader, K. Kittel, C Hanusch, R. Kreienberg, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Jens Huober, Maik Hauschild, S. Loibl, Valentina Nekljudova, Michael Untch, Gϋnter von Minckwitz, (unknown)	2011	23
9	Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group Journal of Clinical Oncology ·Hans-Joachim Lueck, Gϋnter von Minckwitz, Andreas du Bois, Iris Schrader, Jens Huober, V. Heilmann, MW Beckmann, A. Stähle, Christian Jackisch, Christian Marth, Bernhard Richter	2006	22
10	Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group Breast Cancer Research and Treatment ·Hans‐Joachim Lück, Andreas du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V. Heilmann, Matthias W. Beckmann, Ann Stähler, Christian Jackisch, Michael Hubalek, Barbara Richter, Elmar Stickeler, Holger Eidtmann, Christoph Thomssen, Michael Untch, K Wollschläger, Tibor Schuster, Gϋnter von Minckwitz	2013	19
11	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44) Annals of Surgical Oncology ·Bernd Gerber, Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Iris Schrader, K. Kittel, Claus Hanusch, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Jens Huober, Maik Hauschild, Valentina Nekljudova, Sibylle Loibl, Michael Untch	2014	16
12	Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro Journal of Clinical Oncology ·Volkmar Mueller, Sabine Riethdorf, Sibylle Loibl, Martina Komor, J. Houber, Iris Schrader, U. Conrad, Michael Untch, G. vMinckwitz, Klaus Pantel	2007	11
13	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA* Breast Care ·Sibylle Loibl, Dennis Rokitta, Bettina Conrad, Nadia Harbeck, Michaela Wüllner, Mathias Warm, Kathrin Schwedler, Bernd Gerber, Iris Schrader, Holger Eidtmann, Keyur Mehta, Uwe Fuhr, Gϋnter von Minckwitz	2014	10
14	Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto” Cancer Research ·Sabine Riethdorf, Volkmar Mueller, O Mauermann, Thomas Rau, Sibylle Loibl, Holger Eidtmann, Christine Solbach, Hans Tesch, Iris Schrader, K. Kittel, Tanja Fehm, Frank Holms, Michael Untch, Gϋnter von Minckwitz, Klaus Pantel	2010	8
15	5002 MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39) European Journal of Cancer Supplements ·M. Kaufmann, Marc Sütterlin, Iris Schrader, B. Gerber, Wolfgang Bauer, Christoph Mundhenke, W. Wiest, K. Mehta, Sibylle Loibl, Gϋnter von Minckwitz	2009	4
16	Persistance of circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis Journal of Clinical Oncology ·Brigitte Rack, Christian Schindlbeck, Andreas Schneeweiß, Iris Schrader, Robert R. Lorenz, Matthias W. Beckmann, Klaus Pantel, W. Lichtenegger, H. Sommer, W Janni	2009	4
17	First Prospective Cross-Sectional Study on the Impact of Immigration Background and Education in Early Detection of Breast Cancer Breast Care ·Elna Kuehnle, Wulf Siggelkow, Kristina Luebbe, Iris Schrader, Karl-Heinz Noeding, S Noeding, Thomas Noesselt, Peter Hillemanns, Thilo Dörk, Tjoung‐Won Park‐Simon	2020	3
18	P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab. Cancer Research ·Holger Eidtmann, K. Kittel, Mahdi Rezai, Hans Tesch, HU Ulmer, S Stirnberg, Antje Belau, Christine Mau, Elmar Stickeler, Iris Schrader, Peter A. Fasching, C. Salat, Abdelmahmood Abdallah, Frank Holms, Kathrin Schwedler, Valentina Nekljudova, Sibylle Loibl, Minckwitz G von	2011	2
19	Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study. Journal of Clinical Oncology ·Emanuel Bauer, Julia Neugebauer, Ulrich Andergassen, Bernadette Jaeger, J Jueckstock, Peter A. Fasching, Lothar Haeberle, Thomas W. P. Friedl, Iris Schrader, A. Lorenz, Hans Tesch, Mahdi Rezai, Elisabeth Thurner-Herrmanns, Andreas Schneeweiß, Matthias W. Beckmann, Klaus Pantel, Wolfgang Janni, Brigitte Rack	2013	2
20	Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). Journal of Clinical Oncology ·Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Sibylle Loibl, Jens Huober, Hans Tesch, Christine Solbach, Frank Holms, Holger Eidtmann, K. Diedrich, Marianne Just, Michael Clemens, C Hanusch, Iris Schrader, Stephan Henschen, G. M. Hoffmann, Katharina Tiemann, Kurt Diebold, Michael Untch, Carsten Denkert	2011	2

About Iris Schrader

Iris Schrader is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Dermatology and Clinical Biochemistry, having authored 27 papers that have together received 2.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Cells and Metastasis (8 papers), Advanced Breast Cancer Therapies (7 papers), Cancer Genomics and Diagnostics (5 papers), Colorectal Cancer Treatments and Studies (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (874 citations), Immunology (592 citations), Pulmonary and Respiratory Medicine (398 citations) and Pathology and Forensic Medicine (129 citations). Iris Schrader has collaborated with scholars based in Germany, Switzerland and Austria. Frequent co-authors include Gϋnter von Minckwitz, Sibylle Loibl, Martina Komor, Marc Roller, Christine Solbach, Claus Hanusch, Carsten Denkert, Silvia Darb‐Esfahani, Christian von Törne and Knut Engels. Their work appears in journals such as Journal of Clinical Oncology, Breast Care, Cancer Research, Clinical Cancer Research and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact